TumorDiagnostik & Therapie 2018; 39(10): 653-656
DOI: 10.1055/a-0589-1867
Schwerpunkt Diagnostische Methoden in der Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Genomische Signaturen und ihr Stellenwert in der adjuvanten Therapieentscheidung beim frühen Mammakarzinom

Ulrike Nitz
Further Information

Publication History

Publication Date:
04 December 2018 (online)

Welche Patientinnen mit Mammakarzinom profitieren von einer adjuvanten Chemotherapie und welche nicht? Aktuell lösen genomische Tests in der klinischen Praxis die klassische Kombination Pathologie/Immunhistochemie als Grundlage dieser Entscheidung ab.

 
  • Literatur

  • 1 Gluz O, Nitz U, Christgen M. et al. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol 2016; 34: 2341-2349
  • 2 Perou CM, Sorlie T, Eisen MB. et al. Molecular portraits of human breast tumours. Nature 2011; 406: 747-752
  • 3 Curigliano G, Burstein HJ, Winer EP. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Ann Oncol 2017; 28: 1700-1712
  • 4 Wuerstlein R, Grischke EM, Gluz O. et al. Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIME study results. SABCS 2017
  • 5 Baehner FL, Butler S, Badve S. et al. Consistency and control in clinical assay technology over time: Oncotype DX Recurrence score and assessment of single gene expression levels. San Antonio Breast Cancer Symposium 2011 abstract P1–07–11
  • 6 Sestak I, Cuzick J, Dowsett M. et al. Prediction of Late Distant Recurrence After 5 Years of endocrine treatment: A combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. J Clin Oncol 2014; 33: 916-922
  • 7 Sestak I, Dowsett M, Zabaglo L. et al. Comprehensive Comparison of Prognostic Signatures for Breast Cancer Recurrence in TransATAC. SABCS 2016 abstract S6–05
  • 8 Varga Z, Sinn P, Fritzsche F. et al. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One 2013; 8: e58483
  • 9 van’t Veer LJ, Dai H, van de Vijver MJ. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-553
  • 10 Cardoso F, van’t Veer LJ, Bogaerts J. et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-729
  • 11 Paik S, Shak S, Tang G. et al. A multigeneassay to predict recurrence of tamoxifen-treated, node negative breast cancer. N Engl J Med 2004; 351: 2817-2826
  • 12 Sparano JA, Gray RJ, Makower DF. et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373: 2005-2014
  • 13 Sparano JA, Gray RJ, Makower DF. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379: 111-121
  • 14 Gluz O, Nitz U, Christgen M. et al. Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and anthracycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoreginal disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG Plan B trial results. Annals of Oncology 2017; 28 (Suppl. 05) v605-v649